Dendreon's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Dendreon Corporation (DNDN)

Q2 2012 Earnings Conference Call

July 30, 2012, 16:30 p.m. ET


Nicole Soley - IR

John Johnson - Chairman and CEO

Joe DePinto - EVP, Global Commercial Operations

Greg Schiffman - EVP and CFO

Mark Frohlich - EVP, Research and Development and CMO


Mark Schoenebaum - ISI Group

Karen Jay - J.P. Morgan

Rachel McMinn - Bank of America/Merrill Lynch

Salveen Richter - Canaccord Genuity Securities

Eric Schmidt - Cowen and Company

Lee Kalowski - Credit Suisse

David Miller - Biotech Stock Research



Good afternoon, ladies and gentlemen, and welcome to the Second Quarter 2012 Dendreon Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions on how to participate will be given at that time. (Operator Instructions) As a reminder, today’s conference is being recorded.

Now, I’d like to turn the conference over to your host, Nicole Soley.

Nicole Soley

Thank you, and good afternoon, everyone. We’re pleased that you could join us today for our second quarter conference call. With me are John Johnson, Chairman and Chief Executive Officer; Joe DePinto, Executive Vice President of Global Commercial Operations; Greg Schiffman, Executive Vice President and Chief Financial Officer; and Mark Frohlich, Executive Vice President of Research and Development and Chief Medical Officer.

Before we begin, I’d like to remind you that during this call, we will be making forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ from the results discussed in the forward-looking statements. Reference to these risks and uncertainties is made in today’s press release and they are disclosed in detail in our periodic and current event filings with the U.S. Securities and Exchange Commission.

If you liked this article you might like

Biotech-Twitter 2014: A Look Back at the Biotech Year Through the Twitter Lens

Where Are They Now? A Look Back at the Best & Worst Biotech CEOs

Nominees for Absolute Worst Biotechnology CEOs of 2014 Are ...

Using Re-Engineered Immune Cells to Kill Leukemia Induces Lasting Remissions

Stock Market Today: S&P 500 Eyes Strong Finish for 2014; Alibaba Spikes